FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Titel:
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Auteur:
Lorenzen, Sylvie Thuss-Patience, Peter Pauligk, Claudia Gökkurt, Eray Ettrich, Thomas Lordick, Florian Stahl, Michael Reichardt, Peter Sökler, Martin Pink, Daniel Probst, Stefan Hinke, Axel Goetze, Thorsten O. Al-Batran, Salah E.